New Blood Test Offers Faster and More Accurate Tuberculosis Detection
新型血液檢測提供更快速、更精確的結核病診斷
Tuberculosis (TB) remains a major global health threat, killing over a million people every year.
結核病仍是全球主要的健康威脅，每年奪走超過一百萬人的生命。
Furthermore, current blood tests cannot distinguish between latent TB, where the bacteria are dormant, and active TB, which is contagious.
此外，目前的血液檢查無法區分細菌處於休眠狀態的潛伏性結核病，以及具傳染性的活動性結核病。
New blood tests are being developed to identify active TB by detecting specific antibodies or cell-free DNA markers.
新型血液檢查正被開發，旨在透過檢測特定抗體或無細胞DNA標記來識別活動性結核病。
Technologies like CRISPR-based assays allow for rapid, real-time detection, often delivering results in as little as 30 to 120 minutes.
諸如基於CRISPR的檢測技術，可實現快速、即時的檢測，通常能在短短30到120分鐘內提供結果。
These innovative tests are particularly promising for pediatric care, where providing sputum samples is often impossible, and for remote areas where laboratory access is limited.
這些創新檢測對兒科照護特別具有前景，因為兒童通常難以提供痰液樣本；此外，這也適用於實驗室資源受限的偏遠地區。
This shift toward faster, non-invasive, and point-of-care diagnostics is a crucial step in the global strategy to eliminate tuberculosis by 2030, ultimately saving countless lives through earlier and more precise medical intervention.
向更快速、非侵入性且可於照護點進行診斷的轉變，是全球在2030年前消除結核病策略的關鍵一步，最終將透過更早、更精確的醫療干預拯救無數生命。
